Ben is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
291 articles by Ben Fidler
-
FDA panel endorses second shot for adults who received J&J vaccine
Oct. 15, 2021 -
CureVac scraps its first COVID-19 vaccine and pivots to a second
Oct. 12, 2021 -
AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?
Oct. 12, 2021 -
Sarepta outlines final push for Duchenne gene therapy
Oct. 11, 2021 -
Merck, Ridgeback seek US clearance of first oral COVID-19 drug
Oct. 11, 2021 -
Allogene cell therapy trials halted by FDA after unexpected safety finding
Oct. 7, 2021 -
Bristol Myers' top autoimmune drug prospect takes a hit in mid-stage trial
Oct. 7, 2021 -
How a busy year for biotech IPOs measures up at the three-quarter mark
Oct. 4, 2021 -
5 FDA approval decisions to watch in the fourth quarter
Oct. 1, 2021 -
Merck says antiviral pill effective against COVID-19, lifting hopes for first oral drug
Oct. 1, 2021 -
Amicus, looking for a boost, sells its gene therapy work to a SPAC
Sept. 29, 2021 -
Worrisome side effects lead Pfizer to narrow Duchenne gene therapy trial
Sept. 28, 2021 -
Top FDA official takes over vaccine office as agency weighs COVID-19 shots for kids
Sept. 28, 2021 -
'This is the time to double down': Top Vertex executives defend research plan as pressure builds
Sept. 22, 2021 -
Sanofi to buy Kadmon for $1.9B, extending deal streak
Sept. 8, 2021 -
FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety
Sept. 7, 2021 -
At FDA meeting, gene therapy experts wrestle with field's blindspots
Sept. 3, 2021 -
What to expect at the FDA's two-day meeting on gene therapy safety
Sept. 1, 2021 -
Top FDA vaccine officials to leave agency as decision on COVID-19 boosters looms
Aug. 31, 2021 -
J&J, without details, makes case for a coronavirus booster shot
Aug. 25, 2021 -
Novartis falls behind rivals in race to bring CAR-T to early lymphoma
Aug. 24, 2021 -
With new Fate data, same promise, questions surround 'natural killer' cell therapy
Aug. 20, 2021 -
Coherus, known for biosimilars, nears an immunotherapy battle with big pharma
Aug. 19, 2021 -
US to offer coronavirus boosters to all Americans in aggressive plan to counter delta's spread
Aug. 18, 2021 -
Lilly's new eczema drug scores in late-stage studies
Aug. 16, 2021